Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences
The concept that mutant-type ISDR strains may represent a subtype within genotype 1b with a more favourable response towards IFN therapy is supported.
Increasing applicability of liver transplantation for patients with hepatitis B–related liver disease
Based on the experience, hepatitis B patients, including those with active viral replication, should not be excluded from liver transplantation, and excellent long‐term results can be achieved in hepatitis B Patients after liver transplants with modern strategies, and survival rates are similar to other indications.
Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high‐dose hepatitis B immune globulin after liver transplantation
The results suggest that antigenically altered HBV variants s144 and s145 can be selected by HBIG and can influence clinical outcome after liver transplantation.
Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy
Five year survival of European sustained virological responders was similar to the overall population, matched for age and sex, and no HCCs were detected during long term follow up.
RELATION BETWEEN ESCHERICHIA COLI R(ROUGH)-FORMS IN GUT, LIPID A IN LIVER, AND PRIMARY BILIARY CIRRHOSIS
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy.
Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy
Virologic nonresponse can be predicted early at week 12 of treatment independent from the applied therapeutic regimen based on a cutoff level for HCV RNA of 30,000 IU/mL, which recognizes 53.7% of nonresponders previously identified at week 24 of treatment.
Systemic lupus erythematosus: neuropsychiatric signs and symptoms related to cerebral MRI findings
Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV).